Reported Earnings • May 01
Full year 2026 earnings: Revenues and EPS in line with analyst expectations Full year 2026 results: EPS: JP¥744 (up from JP¥581 in FY 2025). Revenue: JP¥947.7b (up 9.4% from FY 2025). Net income: JP¥253.1b (up 25% from FY 2025). Profit margin: 27% (up from 23% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 30
HOYA Corporation, Annual General Meeting, Jun 26, 2026 HOYA Corporation, Annual General Meeting, Jun 26, 2026. Announcement • Apr 21
HOYA Corporation to Report Fiscal Year 2026 Results on Apr 30, 2026 HOYA Corporation announced that they will report fiscal year 2026 results on Apr 30, 2026 Buy Or Sell Opportunity • Apr 08
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 15% to JP¥28,855. The fair value is estimated to be JP¥23,428, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.1% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 7.6% per annum. Earnings are also forecast to grow by 8.0% per annum over the same time period. Declared Dividend • Mar 19
Dividend of JP¥135 announced Shareholders will receive a dividend of JP¥135. Ex-date: 30th March 2026 Payment date: 2nd June 2026 Dividend yield will be 0.9%, which is about the same as the industry average. Payout Ratios Payout ratio: 33%. Cash payout ratio: 27%. Reported Earnings • Jan 31
Third quarter 2026 earnings: EPS and revenues exceed analyst expectations Third quarter 2026 results: EPS: JP¥271 (up from JP¥145 in 3Q 2025). Revenue: JP¥244.7b (up 11% from 3Q 2025). Net income: JP¥91.6b (up 81% from 3Q 2025). Profit margin: 37% (up from 23% in 3Q 2025). The increase in margin was primarily driven by higher revenue. Revenue exceeded analyst estimates by 3.8%. Earnings per share (EPS) also surpassed analyst estimates by 64%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jan 30
HOYA Corporation (TSE:7741) announces an Equity Buyback for 500,000 shares, representing 1.48% for ¥100,000 million. HOYA Corporation (TSE:7741) announces a share repurchase program. Under the program, the company will repurchase up to 500,000 shares, representing 1.48% of its total shares outstanding excluding treasury shares, for a total of ¥100,000 million. The purpose of repurchase program is to strengthen shareholder returns, improve capital efficiency, and implement flexible capital policies. Purchased stocks are planned to be cancelled with the aim of shareholders’ benefit. The repurchase program is valid till July 17, 2026. As of August 1, 2025, the company had 338,078,276 shares outstanding excluding treasury shares and had 336,044 shares in treasury. Reported Earnings • Nov 01
Second quarter 2026 earnings: EPS and revenues exceed analyst expectations Second quarter 2026 results: EPS: JP¥162 (up from JP¥152 in 2Q 2025). Revenue: JP¥234.0b (up 9.0% from 2Q 2025). Net income: JP¥55.4b (up 4.7% from 2Q 2025). Profit margin: 24% (down from 25% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) also surpassed analyst estimates by 7.0%. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Oct 31
HOYA Corporation Announces Interim Dividend for the Fiscal Year Ending March 31, 2026, Payable on November 28, 2025 HOYA Corporation announced that the Board of Directors, at its meeting held on October 31, 2025, resolved to pay the interim dividend of JPY 125.00 per share to the shareholders registered as of September 30, 2025, against previous dividend of JPY 45.00 per share paid a year ago. Date of payment is November 28, 2025. Buy Or Sell Opportunity • Oct 06
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 32% to JP¥22,525. The fair value is estimated to be JP¥18,747, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has grown by 10%. For the next 3 years, revenue is forecast to grow by 5.8% per annum. Earnings are also forecast to grow by 9.1% per annum over the same time period. Announcement • Sep 24
PENTAX Medical and Advanced Sterilization Products Launch the Sterilizable Dec™? Duodenoscope PENTAX Medical, in partnership with Advanced Sterilization Products (ASP), announces the U.S. launch of the Sterilizable DEC™? Duodenoscope, a revolutionary reusable duodenoscope that delivers the predictable handling physicians expect, now with the option for complete sterilization in just 68 minutes using ASP's STERRAD™? System. Unlike single-use alternatives, this next-generation endoscope is engineered for sterility, stability, and control, helping physicians navigate procedures with confidence--while supporting infection prevention and improved operational efficiency. Developed in response to long-standing concerns around cross-contamination, the system enables facilities to enhance infection control with rapid sterilization capabilities and a safer, more sustainable reprocessing experience. Built-in sterilization compatibility allows facilities to tailor workflows without compromising safety--supporting staff, patients, and environmental goals. The product became available in the U.S. beginning July 1, 2025. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥100.00 per share Eligible shareholders must have bought the stock before 29 September 2025. Payment date: 01 December 2025. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of Japanese dividend payers (3.6%). Lower than average of industry peers (1.4%). Announcement • Aug 21
HOYA Corporation (TSE:7741) announces an Equity Buyback for 6,200,000 shares, representing 1.81% for ¥100,000 million. HOYA Corporation (TSE:7741) announces a share repurchase program. Under the program, the company will repurchase up to 6,200,000 shares, representing 1.81% of its total shares outstanding excluding treasury shares, for a total of ¥100,000 million. The purpose of repurchase program is to strengthen shareholder returns, improve capital efficiency, and implement flexible capital policies. The repurchase program is valid till January 21, 2026. As of August 1, 2025, the company had 342,762,990 shares outstanding excluding treasury shares and had 359,630 shares in treasury. Announcement • Aug 20
Hoya Vision Care Raises the Bar with Sun Lenses Designed for Optimum Performance and Lasting Durability HOYA®? Vision Care has raised the bar in sun lens solutions for eye care professionals. This summer alone, HOYA launched three innovative sun lens products: HOYA Polarized™?, HOYA Polarized HEV™?, and HOYA Polarized Lenses with Lumacore™? Mirrors. HOYA's polarized lens portfolio showcases the company's advanced technologies, including embedded mirror coatings, solar blue light filtration, and fashion-forward color options, catering to a wide range of patient lifestyles and visual needs. HOYA Polarized L lenses with Lumacore™?Mirrors are designed for long-lasting performance, using embedded mirror technology that resists scratching, peeling, and fading beyond traditional coatings. By integrating the mirror color directly into the lens, Lumacore ensures superior durability, enhanced clarity, and reduced glare for a more comfortable visual experience. Designed to withstand everyday wear, these lenses are easy to maintain and keep their bold, vibrant look over time. HOYA Polarized™ lenses combine style and performance, offering three fashion-forward colors and gradient options to suit any look. Available in a wide range of designs, including LifeStyle 3 Sun, and compatible with new HOYA mirror coatings, these lenses help reduce glare and unpleasant reflections in excessive sunlight, increasing visual comfort. With features like enhanced contrast for night driving and added UV protection, HOYA Polarized lenses meet everyday lifestyle needs. HOYA Polarized HEV™ lenses provide contrast-rich vision and offer 97% solar blue light protection. They are darker than standard polarized options, improving comfort in bright conditions while enhancing contrast and visual clarity. Designed for durability, they are available in impact-resistant polycarbonate in gray, brown, and green. Now through September 30, 2025, new and current Visionary Alliance members can earn additional rewards on HOYA polarized lenses. The promotion includes HOYA's new HOYA Polarized Lenses with Lumacore™ Mirrors, HOYA Polarized™, and HOYA Polarized HEV™ lens orders. ECPs who wish to participate but aren't currently members can enroll in the program without commitments or contracts. Reported Earnings • Aug 02
First quarter 2026 earnings: Revenues and EPS in line with analyst expectations First quarter 2026 results: EPS: JP¥151 (up from JP¥135 in 1Q 2025). Revenue: JP¥220.9b (up 3.1% from 1Q 2025). Net income: JP¥51.8b (up 9.9% from 1Q 2025). Profit margin: 24% (up from 22% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 6% per year. Declared Dividend • Jul 21
Final dividend increased to JP¥100.00 Dividend of JP¥100.00 is 122% higher than last year. Ex-date: 29th September 2025 Payment date: 1st December 2025 Dividend yield will be 1.2%, which is higher than the industry average of 1.0%. Payout Ratios Payout ratio: 28%. Cash payout ratio: 29%. Announcement • Jun 13
HOYA Corporation Receives Written Verdict from the Tokyo District Court HOYA Corporation announced that it received a written verdict from the Tokyo District Court (the Court) regarding the lawsuit filed to cancel the reassessment based on the transfer pricing taxation. The Company had previously received a reassessment notice from the Tokyo Regional Taxation Bureau in June 2013, based on transfer pricing taxation regarding transactions with Company's overseas subsidiaries from the fiscal year ended March 31, 2007 through the fiscal year ending March 31, 2011. Subsequently, received a written decision from the National Tax Tribunal to rescind a part of the disposition in request for review. However, there is a discrepancy with claim regarding the part of the disposition that was not rescinded, so the filed a lawsuit with the Court in September 2018 to request the revocation of this reassessment and have been submitting with the proceedings. The company has recently received a ruling from the Court that cancels about JPY 1.3 billion in corporate tax, local taxes, and others, out of the amount of the reassessment. The Company disagrees with the other findings of the Court's verdict that maintains portions of the reassessment and expects to appeal to the findings in the Court to seek cancellation of all the reassessments in accordance with the relevant law. This result is not expected to materially impact HOYA's financial performance on a consolidated basis. Reported Earnings • May 02
Full year 2025 earnings: Revenues and EPS in line with analyst expectations Full year 2025 results: EPS: JP¥581 (up from JP¥515 in FY 2024). Revenue: JP¥866.0b (up 14% from FY 2024). Net income: JP¥202.1b (up 11% from FY 2024). Profit margin: 23% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 12% per year. Announcement • May 01
HOYA Corporation, Annual General Meeting, Jun 26, 2025 HOYA Corporation, Annual General Meeting, Jun 26, 2025. Buy Or Sell Opportunity • Mar 31
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 15% to JP¥16,780. The fair value is estimated to be JP¥21,174, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.9% over the last 3 years. Earnings per share has grown by 9.1%. For the next 3 years, revenue is forecast to grow by 7.7% per annum. Earnings are also forecast to grow by 11% per annum over the same time period. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥65.00 per share Eligible shareholders must have bought the stock before 28 March 2025. Payment date: 10 June 2025. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of Japanese dividend payers (3.7%). Lower than average of industry peers (1.1%). Declared Dividend • Mar 06
Dividend of JP¥65.00 announced Dividend of JP¥65.00 is the same as last year. Ex-date: 28th March 2025 Payment date: 10th June 2025 Dividend yield will be 0.6%, which is lower than the industry average of 1.0%. Payout Ratios Payout ratio: 11%. Cash payout ratio: 19%. Announcement • Feb 28
HOYA Corporation to Report Fiscal Year 2025 Results on May 01, 2025 HOYA Corporation announced that they will report fiscal year 2025 results on May 01, 2025 Reported Earnings • Feb 04
Third quarter 2025 earnings: EPS misses analyst expectations Third quarter 2025 results: EPS: JP¥145 (up from JP¥110 in 3Q 2024). Revenue: JP¥220.8b (up 13% from 3Q 2024). Net income: JP¥50.5b (up 31% from 3Q 2024). Profit margin: 23% (up from 20% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.9%. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 8% per year. Announcement • Feb 03
HOYA Corporation (TSE:7741) announces an Equity Buyback for 3,000,000 shares, representing 0.87% for ¥50,000 million. HOYA Corporation (TSE:7741) announces a share repurchase program. Under the program, the company will repurchase up to 3,000,000 shares, representing 0.87% of its total shares outstanding excluding treasury shares, for a total of ¥50,000 million. The purpose of repurchase program is to strengthen shareholder returns, improve capital efficiency, and implement flexible capital policies. The repurchase program is valid till April 21, 2025. As of February 3, 2025, the company had 345,481,111 shares outstanding excluding treasury shares and had 2,845,309 shares in treasury. Reported Earnings • Nov 02
Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Second quarter 2025 results: EPS: JP¥152 (up from JP¥134 in 2Q 2024). Revenue: JP¥214.7b (up 9.5% from 2Q 2024). Net income: JP¥52.9b (up 12% from 2Q 2024). Profit margin: 25% (in line with 2Q 2024). Revenue exceeded analyst estimates by 4.6%. Earnings per share (EPS) also surpassed analyst estimates by 4.5%. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 5% per year. Announcement • Nov 01
HOYA Corporation (TSE:7741) announces an Equity Buyback for 3,000,000 shares, representing 0.86% for ¥50,000 million. HOYA Corporation (TSE:7741) announces a share repurchase program. Under the program, the company will repurchase up to 3,000,000 shares, representing 0.86% of its total shares outstanding excluding treasury shares, for a total of ¥50,000 million. The purpose of repurchase program is to strengthen shareholder returns, improve capital efficiency, and implement flexible capital policies. The repurchase program is valid till January 22, 2025. As of September 30, 2024, the company had 347,922,719 shares outstanding excluding treasury shares and had 3,036,001 shares in treasury. Announcement • Oct 31
HOYA Corporation Announces Interim Dividend for the Fiscal Year Ending March 31, 2025, Payable on November 29, 2024 HOYA Corporation announced that the Board of Directors, at its meeting held on October 31, 2024, resolved to pay the interim dividend of JPY 45.00 per share to the shareholders registered as of September 30, 2024, against previous dividend of JPY 45.00 per share paid a year ago. Date of payment is November 29, 2024. Upcoming Dividend • Sep 20
Upcoming dividend of JP¥45.00 per share Eligible shareholders must have bought the stock before 27 September 2024. Payment date: 02 December 2024. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of Japanese dividend payers (3.8%). Lower than average of industry peers (1.0%). Announcement • Aug 06
Advanced Sterilization Products Announces FDA Clearance for Revolutionary Sterilization Cycle for Duodenoscopes in Partnership with PENTAX Medical, a Division of HOYA Advanced Sterilization Products (ASP), a division of Fortive, in collaboration with PENTAX Medical, a division of HOYA, announced the FDA clearance of the new ULTRA GI™ Cycle in its product, the STERRAD™ 100NX Sterilizer with ALLClear™ Technology. The ULTRA GI™ Cycle is specifically and uniquely designed to reprocess duodenoscopes using hydrogen peroxide gas plasma sterilization. The FDA clearance marks a significant milestone in advancing patient safety and addressing the challenges associated with current reprocessing methods for duodenoscopes. This sterilization cycle is set to revolutionize sterilization practices in healthcare facilities, ensuring a new standard of safety and efficacy. Duodenoscopes have been under scrutiny due to their relatively high contamination rates, prompting the urgent need for a robust sterilization solution. The collaborative effort between ASP and PENTAX Medical has resulted in an innovative method that not only meets but exceeds industry standards, providing healthcare professionals with a powerful tool to enhance patient safety. Buy Or Sell Opportunity • Aug 05
Now 27% undervalued after recent price drop Over the last 90 days, the stock has fallen 13% to JP¥16,065. The fair value is estimated to be JP¥21,949, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has grown by 8.0%. For the next 3 years, revenue is forecast to grow by 7.7% per annum. Earnings are also forecast to grow by 11% per annum over the same time period. Reported Earnings • Aug 03
First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2025 results: EPS: JP¥135 (up from JP¥108 in 1Q 2024). Revenue: JP¥213.8b (up 17% from 1Q 2024). Net income: JP¥47.2b (up 23% from 1Q 2024). Profit margin: 22% (up from 21% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) missed analyst estimates by 4.2%. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Declared Dividend • Jul 18
Final dividend of JP¥45.00 announced Dividend of JP¥45.00 is the same as last year. Ex-date: 27th September 2024 Payment date: 2nd December 2024 Dividend yield will be 0.6%, which is lower than the industry average of 1.0%. Payout Ratios Payout ratio: 21%. Cash payout ratio: 21%. Buy Or Sell Opportunity • Jul 01
Now 8.4% overvalued The stock has been flat over the last 90 days, currently trading at JP¥18,570. The fair value is estimated to be JP¥17,134, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.5% over the last 3 years. Earnings per share has grown by 9.0%. For the next 3 years, revenue is forecast to grow by 7.2% per annum. Earnings are also forecast to grow by 10% per annum over the same time period. Buy Or Sell Opportunity • Jun 26
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 1.3% to JP¥19,085. The fair value is estimated to be JP¥15,895, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.5% over the last 3 years. Earnings per share has grown by 9.0%. For the next 3 years, revenue is forecast to grow by 6.9% per annum. Earnings are also forecast to grow by 9.7% per annum over the same time period. Reported Earnings • Jun 25
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: JP¥515 (up from JP¥470 in FY 2023). Revenue: JP¥762.6b (up 5.4% from FY 2023). Net income: JP¥181.4b (up 7.6% from FY 2023). Profit margin: 24% (in line with FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.1%. Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 8% per year. Buy Or Sell Opportunity • May 31
Now 21% overvalued Over the last 90 days, the stock has fallen 4.4% to JP¥19,060. The fair value is estimated to be JP¥15,789, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.5% over the last 3 years. Earnings per share has grown by 9.0%. For the next 3 years, revenue is forecast to grow by 6.8% per annum. Earnings are also forecast to grow by 9.2% per annum over the same time period. Announcement • May 25
Hoya Corporation Announces Dividend for the Year Ending March 31, 2024, Payable on June 10, 2024 HOYA Corporation announced dividend of JPY 65 per share compared to JPY 65 per share a year ago. Date of payment June 10, 2024. Announcement • May 17
HOYA Corporation, Annual General Meeting, Jun 27, 2024 HOYA Corporation, Annual General Meeting, Jun 27, 2024. Reported Earnings • May 17
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: JP¥515 (up from JP¥470 in FY 2023). Revenue: JP¥762.6b (up 5.4% from FY 2023). Net income: JP¥181.4b (up 7.6% from FY 2023). Profit margin: 24% (in line with FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.1%. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year and the company’s share price has also increased by 9% per year. Announcement • May 16
HOYA Corporation (TSE:7741) announces an Equity Buyback for 3,000,000 shares, representing 0.86% for ¥50,000 million. HOYA Corporation (TSE:7741) announces a share repurchase program. Under the program, the company will repurchase up to 3,000,000 shares, representing 0.86% of its total shares outstanding excluding treasury shares, for a total of ¥50,000 million. The purpose of repurchase program is to strengthen shareholder returns, improve capital efficiency, and implement flexible capital policies. The repurchase program is valid till August 15, 2024. As of March 31, 2024, the company had 350,521,475 shares outstanding excluding treasury shares and had 437,245 shares in treasury. Buy Or Sell Opportunity • May 15
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 5.2% to JP¥19,280. The fair value is estimated to be JP¥15,890, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 6.7% per annum. Earnings are also forecast to grow by 10% per annum over the same time period. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥65.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 03 June 2024. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of Japanese dividend payers (3.2%). Lower than average of industry peers (0.9%). Declared Dividend • Mar 02
Dividend of JP¥65.00 announced Dividend of JP¥65.00 is the same as last year. Ex-date: 28th March 2024 Payment date: 3rd June 2024 Dividend yield will be 0.6%, which is lower than the industry average of 1.0%. Payout Ratios Payout ratio: 33%. Cash payout ratio: 23%. Announcement • Mar 02
HOYA Corporation to Report Fiscal Year 2024 Results on May 01, 2024 HOYA Corporation announced that they will report fiscal year 2024 results on May 01, 2024 Reported Earnings • Feb 03
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2024 results: EPS: JP¥110 (up from JP¥85.89 in 3Q 2023). Revenue: JP¥194.8b (up 11% from 3Q 2023). Net income: JP¥38.7b (up 26% from 3Q 2023). Profit margin: 20% (up from 17% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) missed analyst estimates by 7.6%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 12% per year. Announcement • Nov 02
Hoya Corporation Announces Interim Dividend for the Six Months Ended September 30, 2023 HOYA Corporation announced interim dividend of JPY 45.00 per share for the six months ended September 30, 2023 compared to JPY 45.00 per share paid a year ago. Reported Earnings • Nov 02
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Second quarter 2024 results: EPS: JP¥134 (up from JP¥131 in 2Q 2023). Revenue: JP¥188.7b (flat on 2Q 2023). Net income: JP¥47.4b (flat on 2Q 2023). Profit margin: 25% (in line with 2Q 2023). Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 6.4%. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Sep 21
Upcoming dividend of JP¥45.00 per share at 0.7% yield Eligible shareholders must have bought the stock before 28 September 2023. Payment date: 30 November 2023. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of Japanese dividend payers (3.3%). Lower than average of industry peers (1.1%). Announcement • Aug 27
HOYA Corporation to Report Q3, 2024 Results on Feb 01, 2024 HOYA Corporation announced that they will report Q3, 2024 results on Feb 01, 2024 Reported Earnings • Aug 01
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2024 results: EPS: JP¥108 (down from JP¥133 in 1Q 2023). Revenue: JP¥182.3b (up 1.2% from 1Q 2023). Net income: JP¥38.2b (down 21% from 1Q 2023). Profit margin: 21% (down from 27% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates by 3.0%. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 18% per year. Announcement • Aug 01
HOYA Corporation (TSE:7741) announces an Equity Buyback for 3,600,000 shares, representing 1.02% for ¥50,000 million. HOYA Corporation (TSE:7741) announces a share repurchase program. Under the program, the company will repurchase up to 3,600,000 shares, representing 1.02% of its total outstanding share capital, excluding treasury stock, for a total purchase price of ¥50,000 million. The purpose of the program is to enhance shareholder returns, improve capital efficiency, and implement flexible capital policies. The program will continue through October 20, 2023. As of July 25, 2023, the company had 353,625,331 outstanding shares (excluding treasury stock) and 463,189 treasury shares. Announcement • Jul 29
HOYA Corporation to Report Q2, 2024 Results on Oct 31, 2023 HOYA Corporation announced that they will report Q2, 2024 results on Oct 31, 2023 Announcement • Jun 28
HOYA Corporation to Report Q1, 2024 Results on Jul 31, 2023 HOYA Corporation announced that they will report Q1, 2024 results on Jul 31, 2023 Reported Earnings • May 09
Full year 2023 earnings: Revenues and EPS in line with analyst expectations Full year 2023 results: EPS: JP¥470 (up from JP¥446 in FY 2022). Revenue: JP¥723.6b (up 9.4% from FY 2022). Net income: JP¥168.6b (up 2.5% from FY 2022). Profit margin: 23% (down from 25% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 15% per year. Announcement • Feb 01
HOYA Corporation (TSE:7741) announces an Equity Buyback for 3,600,000 shares, representing 1.01% for ¥40,000 million. HOYA Corporation (TSE:7741) announces a share repurchase program. Under the program, the company will repurchase up to 3,600,000 shares, representing 1.01% of its total outstanding share capital, excluding treasury stock, for a total purchase price of ¥40,000 million. The purpose of the program is to enhance shareholder returns, improve capital efficiency, and implement flexible capital policies. The program will continue through April 20, 2023. As of January 25, 2023, the company had 356,434,731 outstanding shares (excluding treasury stock) and 525,789 treasury shares. Reported Earnings • Feb 01
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Third quarter 2023 results: EPS: JP¥85.90 (down from JP¥111 in 3Q 2022). Revenue: JP¥173.5b (up 1.3% from 3Q 2022). Net income: JP¥30.6b (down 25% from 3Q 2022). Profit margin: 18% (down from 24% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 15%. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Announcement • Dec 28
HOYA Corporation to Report Q3, 2023 Results on Jan 31, 2023 HOYA Corporation announced that they will report Q3, 2023 results on Jan 31, 2023 Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Mika Nishimura was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 28
Second quarter 2023 earnings: EPS exceeds analyst expectations Second quarter 2023 results: EPS: JP¥131 (up from JP¥116 in 2Q 2022). Revenue: JP¥184.1b (up 13% from 2Q 2022). Net income: JP¥47.1b (up 9.6% from 2Q 2022). Profit margin: 26% (in line with 2Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.3%. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 14% per year. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥45.00 per share Eligible shareholders must have bought the stock before 29 September 2022. Payment date: 30 November 2022. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of Japanese dividend payers (3.7%). Lower than average of industry peers (1.0%). 
